Forced return of a batch of large varieties without centralized purchase

29 large variety purchase volume was announced, and key monitored varieties were excluded and forced return was encountered Recently, the Bureau of human resources and social security of Jinhua City, Zhejiang Province issued the announcement on the first batch of drugs in Jinhua City The purchase volume of 29 large varieties was announced: ceftriaxone sodium, acarbose, valsartan (see the attachment for details) For the formation of the first batch of volume purchase catalogue, the official statement is that according to the purchase data on the 2018 Zhejiang Pharmaceutical machinery purchase platform, according to the drugs with the same general name (prescribed dosage form, specification, quality level) in the top of the total purchase amount (excluding the national 4 + 7 negotiation drugs, national supervision and control catalogue products, etc.), the purchase volume in 2018 is counted, and the estimated purchase volume in 2020 is calculated (according to 2018 Statistics of 60% of purchase volume) At last, the first batch of products and quantity purchased with quantity will be determined by the negotiation expert group According to the catalogue of Jinhua City this time, the key monitored varieties have been excluded from centralized procurement, that is to say, they will not be used on a large scale for at least one year There is a big crisis in the use of key monitoring drugs in hospitals According to the medical representative, Suzhou Municipal Health and Health Commission released the Sixth Batch of key monitoring and rational use drugs catalogue in Suzhou, which includes 20 varieties, consistent with the national version After the release of the catalogue, the pharmacists have received the notice from the commercial companies that their products listed in the catalogue are required to be returned It is said that most varieties face this situation in Suzhou, even if they are not sold out, they will be forced to return Back in Jinhua City, the document gives the exact purchase volume, and correspondingly requires that the price of drugs be lowered, that is to say, price reduction According to this document, the price quoted by drug manufacturers should include all taxes and fees, including distribution expenses; at the same time, according to the current payment standard of Zhejiang medical insurance, the decrease of drugs should not be less than 10%, and this quotation should not be higher than the actual purchase price of all hospitals in Jinhua City (including the price reduction in other ways); in addition, the manufacturers participating in the quotation are regarded as commitments The medicine can be used as a replacement and standby to ensure that the cancelled medicine can be replaced in time Jinhua city stressed that if the above principles are violated, the offer will be treated as invalid The price reduction is a key factor According to the scoring standard for the first batch of drugs with volume purchase, 25 points will be given for the first place, 20 points will be given for the second place, 15 points will be given for the third place, and 10 points will be given for the fourth place However, Jinhua said that the drug volume purchase price is not linked Similar to the previous volume purchase, Jinhua city also requires enterprises to guarantee the supply In addition to force majeure, the shortlisted enterprises with quality and supply problems shall bear the additional costs incurred by drug replacement, otherwise it will be deemed as dishonest behavior All products of relevant dishonest enterprises shall not be sold in all member units of the municipal procurement alliance within two years At the same time, the member units of the purchasing alliance are also required to improve the collection rate and settle accounts with the enterprise in a timely manner according to the provisions of the agreement The period from the acceptance of goods to the payment shall not exceed 30 days In terms of medical insurance payment, medical institutions are required to use drugs of the same negotiated variety that are higher than the medical insurance payment standard, and the part that is higher than the medical insurance payment standard will not be paid by the overall planning fund; the part that is lower than the medical insurance payment standard will still be paid according to the original medical insurance payment standard Medical insurance designated drugstores shall sell at a price that does not rise more than 15% of the actual purchase price.